Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H2S1
UPID:
KCNN2_HUMAN
Alternative names:
KCa2.2
Alternative UPACC:
Q9H2S1; A6NF94; Q0VFZ4; Q6PJI0; Q6X2Y2
Background:
Small conductance calcium-activated potassium channel protein 2 (KCa2.2) plays a pivotal role in neuronal excitability regulation. It forms a voltage-independent potassium channel activated by intracellular calcium, leading to membrane hyperpolarization. This process is crucial for the slow component of synaptic afterhyperpolarization, influencing neuronal signaling.
Therapeutic significance:
KCa2.2 is implicated in Dystonia 34, myoclonic, and neurodevelopmental disorders with or without movement or behavioral abnormalities. These associations highlight its potential as a target for therapeutic intervention in neurological conditions characterized by involuntary muscle contractions, developmental delays, and intellectual disabilities.